EZH2 and lymphoma: Of VUS mutations, 3% led to an observable gain- or switch-of-function, including one with alterations in product specificity similar to those observed in a SET domain of EZH2, which is currently being targeted by therapeutics as a lymphoma treatment71,72,78–80.